Respiratory virus season has arrived, and hopefully you’re up to date on vaccinations that can help prevent infectious ...

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...

Clesrovimab is an extended half-life RSV neutralizing antibody in development for all infants in their first RSV season and ...

(Corrects headline, paragraph 1 and 2 in Oct. 17 story to show the drug reduced medically attended lower respiratory ...

The term “immunity debt” is being used to describe how countries are seeing an increase in viral infections, particularly ...

There’s been an uptick in viral infections in the post-pandemic period, but that isn’t necessarily a bad thing.View on ...

Merck's (MRK) monoclonal antibody clesrovimab shows cuts RSV infections by 60% in infants, with a strong safety profile. Read ...

Health experts highlight how this highly contagious disease affects vulnerable populations and share insights on prevention ...

Study explores the clinical manifestations, risk factors, and 90-day mortality outcomes in adults hospitalized with RSV or ...

A mother’s worst nightmare is watching her child fall gravely ill, feeling helpless as the condition becomes worse. When ...

Clesrovimab (MK-1654), an Investigational RSV Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and ...